Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas

The PI3K/Akt/mTOR (PAM) axis is constitutively activated in multiple lymphoma subtypes and is a promising therapeutic target. The mTOR inhibitor temsirolimus (TEM) and the immunomodulatory agent lenalidomide (LEN) have overlapping effects within the PAM axis with synergistic potential. This multice...

Ausführliche Beschreibung

Gespeichert in:

Bibliografische Detailangaben
Hauptverfasser:	Ajay Major, Justin Kline, Theodore G. Karrison, Paul A. S. Fishkin, Amy S. Kimball, Adam M. Petrich, Sreenivasa Nattam, Krishna Rao, Bethany G. Sleckman, Kenneth Cohen, Koen van Besien, Aaron P. Rapoport, Sonali M. Smith
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Ferrata Storti Foundation 2021-07-01
Schriftenreihe:	Haematologica
Online-Zugang:	https://haematologica.org/article/view/10347
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!

Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas

Ähnliche Einträge